AVP-923-30

DRUG2 trials

Sponsors

Avanir Pharmaceuticals

Conditions

AgitationAlzheimer's DiseaseCentral Neuropathic PainMultiple Sclerosis

Phase 2

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

CompletedNCT01324232

Avanir PharmaceuticalsCentral Neuropathic Pain, Multiple Sclerosis

Start: 2011-09-08End: 2013-09-26Updated: 2021-11-22

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

CompletedNCT01584440

Avanir PharmaceuticalsAgitation, Alzheimer's Disease

Start: 2012-08-13End: 2014-07-30Updated: 2021-11-26

Related Papers

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia

JAMA2015-09-22197 citations